Lazard Asset Management
RYTM icon

Lazard Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Lazard Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.86M Buy
32,888
+7,317
+29% +$712K ﹤0.01% 750
2025
Q4 		$2.74M Sell
25,571
-4,668
-15% -$495K ﹤0.01% 744
2025
Q3 		$3.05M Sell
30,239
-69,206
-70% -$6.43M ﹤0.01% 731
2025
Q2 		$6.28M Sell
99,445
-3,757
-4% -$230K 0.01% 672
2025
Q1 		$5.46M Sell
103,202
-3,059
-3% -$170K 0.01% 657
2024
Q4 		$5.95M Buy
+106,261
New +$5.87M 0.01% 593
2024
Q2 		– Sell
-1,733
Closed -$75K – 2401
2024
Q1 		$75K Sell
1,733
-124
-7% -$5.43K ﹤0.01% 1623
2023
Q4 		$85K Buy
+1,857
New +$58.6K ﹤0.01% 1720

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Lazard Asset Management's RYTM Position: Q1 2026 in Review

Lazard Asset Management increased its Rhythm Pharmaceuticals (RYTM) stake by 29% in Q1 2026, buying an estimated $712K and bringing the position to 32,888 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #750.

Lazard Asset Management first reported a position in RYTM in Q4 2023 and has held it in 8 quarters since. The position peaked at $6.28M in Q2 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Lazard Asset Management held 32,888 shares of Rhythm Pharmaceuticals worth $2.86M as of Q1 2026.
  • Lazard Asset Management bought 7,317 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $712K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #750 holding.
  • Lazard Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • Lazard Asset Management's Rhythm Pharmaceuticals position peaked at $6.28M in Q2 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.